# EDGAR Filing Document

**Accession Number:** 0001736730
**File Stem:** 0001953107-26-000005
**Filing Date:** 2026-3
**Character Count:** 10427
**Document Hash:** bba34f28fe560a36edd3b580e0d4b530
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001953107-26-000005.hdr.sgml**: 20260311

**ACCESSION NUMBER**: 0001953107-26-000005

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260311

**DATE AS OF CHANGE**: 20260311

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Camp4 Therapeutics Corp
- **CENTRAL INDEX KEY:** 0001736730
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94655
- **FILM NUMBER:** 26744741

**BUSINESS ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-651-8867

**MAIL ADDRESS:**
- **STREET 1:** ONE KENDALL SQUARE
- **STREET 2:** BUILDING 1400 WEST, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enavate Sciences GP, LLC
- **CENTRAL INDEX KEY:** 0001953107

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 106 W 56TH ST.
- **STREET 2:** FLOOR 8
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 212-909-3022

**MAIL ADDRESS:**
- **STREET 1:** 106 W 56TH ST.
- **STREET 2:** FLOOR 8
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**CAMP4 THERAPEUTICS CORPORATION**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**13463J101**

*(CUSIP Number)*

**James P. Boylan**<br>Enavate Sciences<br>106 W 56th Street, 8th Floor<br>New York NY 10019<br>(332) 275-5551

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/09/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **13463J101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Enavate Sciences GP, LLC** | Name of reporting person<br>**Enavate Sciences GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2495562.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2495562.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2495562.00** | Aggregate amount beneficially owned by each reporting person<br>**2495562.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.8%** | Percent of class represented by amount in Row (11)<br>**4.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **13463J101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Everest Aggregator, LP** | Name of reporting person<br>**Everest Aggregator, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2495562.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2495562.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2495562.00** | Aggregate amount beneficially owned by each reporting person<br>**2495562.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.8%** | Percent of class represented by amount in Row (11)<br>**4.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
CAMP4 THERAPEUTICS CORPORATION

**(c) Address of Issuer's Principal Executive Offices:**
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, 02139

This Amendment No. 3 (this "Amendment No. 3" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 and amended on September 15, 2025 and December 23, 2025 (as amended, the "Statement") by the Reporting Entities. Unless otherwise defined herein, capitalized terms used in this Amendment No. 3 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon 51,919,321 shares of Common Stock outstanding as of March 4, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 5, 2026.

Everest LP directly holds 2,495,562 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP.

**(b)**
Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

**(c)**
Except as set forth below, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days.

On January 12, 2026, Everest LP sold an aggregate of 497 shares in open market transactions at prices ranging from $6.05 to $6.20 (weighted average sales price of $6.11 per share).

On January 14, 2026, Everest LP sold an aggregate of 11,228 shares in open market transactions at prices ranging from $6.00 to $6.05 (weighted average sales price of $6.00 per share).

On February 25, 2026, Everest LP sold an aggregate of 7,561 shares in open market transactions at prices ranging from $4.50 to $4.62 (weighted average sales price of $4.59 per share).

On February 26, 2026, Everest LP sold an aggregate of 5,413 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.54 per share).

On February 27, 2026, Everest LP sold an aggregate of 2,395 shares in open market transactions at prices ranging from $4.50 to $4.72 (weighted average sales price of $4.63 per share).

On March 2, 2026, Everest LP sold an aggregate of 6,926 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.52 per share).

On March 9, 2026, Everest LP sold an aggregate of 91,699 shares in open market transactions at prices ranging from $6.50 to $7.15 (weighted average sales price of $6.69 per share).

On March 10, 2026, Everest LP sold an aggregate of 99,639 shares in open market transactions at prices ranging from $5.55 to $6.35 (weighted average sales price of $5.83 per share).

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Enavate Sciences GP, LLC

**Signature:** /s/ James P. Boylan

**Name/Title:** By James P. Boylan, Manager

**Date:** 03/11/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Everest Aggregator, LP

**Signature:** /s/ James P. Boylan

**Name/Title:** By: Enavate Sciences GP, LLC, its General Partner, By James P. Boylan, Manager

**Date:** 03/11/2026